539 related articles for article (PubMed ID: 28441991)
1.
Kowal K; Bielecki P; DuBuske IV; DuBuske LM
Allergy Asthma Proc; 2017 May; 38(3):204-215. PubMed ID: 28441991
[TBL] [Abstract][Full Text] [Related]
2. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.
Macglashan DW; Saini SS
J Allergy Clin Immunol; 2013 Oct; 132(4):906-11.e1-4. PubMed ID: 23791510
[TBL] [Abstract][Full Text] [Related]
4. In vitro basophil histamine-releasing activity of circulating IgG1 and IgG4 autoanti-IgE antibodies from asthma patients and the demonstration that anti-IgE modulates allergen-induced basophil activation.
Shakib F; Smith SJ
Clin Exp Allergy; 1994 Mar; 24(3):270-5. PubMed ID: 7516815
[TBL] [Abstract][Full Text] [Related]
5. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.
Oliver JM; Tarleton CA; Gilmartin L; Archibeque T; Qualls CR; Diehl L; Wilson BS; Schuyler M
Int Arch Allergy Immunol; 2010; 151(4):275-84. PubMed ID: 19844128
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
7. [An attempt to block histamine release from basophils granulocytes with antibodies obtained as a result of long-term immunization].
Szymaniak L
Ann Acad Med Stetin; 1998; 44():45-64. PubMed ID: 9857531
[TBL] [Abstract][Full Text] [Related]
8. Study of IgE-dependent basophil releasability in allergic patients.
Sanz ML; Latasa M; García BE; Gato JJ; Oehling A
J Investig Allergol Clin Immunol; 1991 Oct; 1(5):293-301. PubMed ID: 1727011
[TBL] [Abstract][Full Text] [Related]
9. Introduction: basophil histamine release and the diagnosis of food allergy.
Du Buske LM
Allergy Proc; 1993; 14(4):243-9. PubMed ID: 7693545
[TBL] [Abstract][Full Text] [Related]
10. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation.
Nopp A; Johansson SG; Ankerst J; Bylin G; Cardell LO; Grönneberg R; Irander K; Palmqvist M; Oman H
Allergy; 2006 Mar; 61(3):298-302. PubMed ID: 16436137
[TBL] [Abstract][Full Text] [Related]
11. Activation of Human Basophils by A549 Lung Epithelial Cells Reveals a Novel IgE-Dependent Response Independent of Allergen.
Schroeder JT; Bieneman AP
J Immunol; 2017 Aug; 199(3):855-865. PubMed ID: 28652400
[TBL] [Abstract][Full Text] [Related]
12. IgE antibody-specific activity in human allergic disease.
Hamilton RG; MacGlashan DW; Saini SS
Immunol Res; 2010 Jul; 47(1-3):273-84. PubMed ID: 20066506
[TBL] [Abstract][Full Text] [Related]
13. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
Eckman JA; Sterba PM; Kelly D; Alexander V; Liu MC; Bochner BS; Macglashan DW; Saini SS
J Allergy Clin Immunol; 2010 Apr; 125(4):889-895.e7. PubMed ID: 19962744
[TBL] [Abstract][Full Text] [Related]
14. Analysis of anti-IgE and allergen induced human basophil activation by flow cytometry. Comparison with histamine release.
Sainte-Laudy J; Sabbah A; Vallon C; Guerin JC
Inflamm Res; 1998 Oct; 47(10):401-8. PubMed ID: 9831325
[TBL] [Abstract][Full Text] [Related]
15. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.
Bush RK
Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893
[TBL] [Abstract][Full Text] [Related]
16. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors.
MacGlashan DW; Savage JH; Wood RA; Saini SS
J Allergy Clin Immunol; 2012 Nov; 130(5):1130-1135.e5. PubMed ID: 22800400
[TBL] [Abstract][Full Text] [Related]
17. Basophil histamine release and leukotriene production in response to anti-IgE and anti-IgE receptor antibodies. Comparison of normal subjects and patients with urticaria, atopic dermatitis or bronchial asthma.
Bischoff SC; Zwahlen R; Stucki M; Müllner G; de Weck AL; Stadler BM; Dahinden CA
Int Arch Allergy Immunol; 1996 Jul; 110(3):261-71. PubMed ID: 8688673
[TBL] [Abstract][Full Text] [Related]
18. A comparative study on basophil activation test, histamine release assay, and passive sensitization histamine release assay in the diagnosis of peanut allergy.
Larsen LF; Juel-Berg N; Hansen KS; Clare Mills EN; van Ree R; Poulsen LK; Jensen BM
Allergy; 2018 Jan; 73(1):137-144. PubMed ID: 28686296
[TBL] [Abstract][Full Text] [Related]
19. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
20. Allergen-induced basophil activation: CD63 cell expression detected by flow cytometry in patients allergic to Dermatophagoides pteronyssinus and Lolium perenne.
Sanz ML; Sánchez G; Gamboa PM; Vila L; Uasuf C; Chazot M; Diéguez I; De Weck AL
Clin Exp Allergy; 2001 Jul; 31(7):1007-13. PubMed ID: 11467990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
